Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study.

Indian journal of pathology & microbiology - 1 Jan 2000

Md Pauzi Suria Hayati, Masir Noraidah, Yahaya Azyani, Mohammed Fazarina, Tizen Laim Nur Maya Sabrina, Mustangin Muatamarulain, Aizudin Azimatun Noor, Talib Arni, Teoh Kean-Hooi, Karim Norain, Oy-Leng Jacqueline Wong, Rajadurai Pathmanathan

Abstract excerpt

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) over-expression in breast cancer is associated with aggressive tumor behavior and predicts response to targeted therapy. Accurate HER2 result is paramount for optimal patient management. However, routine HER2 immunohistochemistry (IHC) testing are subjected to intra- and inter-laboratory variability. OBJECTIVE: This study aims to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Carcinoma

Share to Genes, erbB-2

Share to Immunohistochemistry

Share to Receptor, ErbB-2

Share to Reproducibility of Results

Source

Identifiers

PMID: 34673585
DOI: 10.4103/IJPM.IJPM_983_20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study.PMID 34673585Read ↗

Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in ChinaSemantic proximity Read ↗

Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and GuidelinesSemantic proximity Read ↗

Clinical Laboratory Assays for HER-2/ <i>neu</i> Amplification and OverexpressionSemantic proximity Read ↗

Multi-institutional Assessment of Pathologist scoring HER2 ImmunohistochemistrySemantic proximity Read ↗

Impact of a machine learning-powered algorithm on pathologist HER2 IHC scoring in breast cancerSemantic proximity Read ↗

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity Read ↗

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.Semantic proximity Read ↗

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read ↗

Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast CancerSemantic proximity Read ↗

High-Content, Cell-by-Cell Assessment of HER2 Overexpression and Amplification for Heterogeneity Detection in Breast CancerSemantic proximity Read ↗

Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel RecommendationsSemantic proximity Read ↗

Artificial Intelligence Model’s assessment of intra-sample heterogeneity of HER2 IHC in breast cancer is related to interobserver and intraobserver agreement among pathologistsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.